MNTA Momenta Pharmaceuticals Inc.

14.4
+0.25  (+2%)
Previous Close 14.15
Open 13.82
Price To Book 4.54
Market Cap 1,421,385,149
Shares 98,707,302
Volume 559,769
Short Ratio
Av. Daily Volume 437,416
Stock charts supplied by TradingView

NewsSee all news

  1. Momenta Pharmaceuticals Appoints Dr. Donna Grogan to Board of Directors

    CAMBRIDGE, Mass., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial met primary endpoint - November 29, 2016.
M923
Moderate-to-severe chronic plaque psoriasis
Filed 2007. Approved April 16 2015.
Generic Copaxone
Multiple sclerosis
Phase 2 development discontinued due to poor efficacy shown
Necuparanib (MOM-M402-103)
Advanced metastatic pancreatic cancer
Phase 1 trial ongoing.
M230 (CSL730)
Healthy volunteers
Phase 2 data due 2020.
M281
generalized myasthenia gravis (gMG)
Phase 2 data due 2021.
M281
hemolytic disease of the fetus and newborn (HDFN)
Phase 1/2 initial data due 1H 2020.
M254
Immune Thrombocytopenic Purpura (ITP)
Phase 2 data due 2021.
M281
Warm Autoimmune Hemolytic Anemia (wAIHA)

Latest News

  1. Momenta Pharmaceuticals Appoints Dr. Donna Grogan to Board of Directors

    CAMBRIDGE, Mass., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated